@entity299 account for almost 50% of deaths in long-term dialysis @entity1 . Left @entity67 is present in approximately 80% of these @entity1 and is highly predictive of future @entity741 , @entity712 , and @entity204 . @entity417 has been identified as one of several risk factors responsible for @entity299 . Cardiovascular consequences of @entity8 begin relatively early in the course of @entity177 and progress with the decline of renal function and also during dialysis therapy. In @entity177 @entity1 with severe @entity417 (hemoglobin levels <10 g/dL), @entity5691 , high left ventricular mass, @entity299 improve after partial correction of @entity417 (hemoglobin levels >11 g/dL according to the European Best Practice Guidelines). It is disappointing that normalization of hemoglobin levels has only minor effects with respect to regression of @entity4346 and @entity5988 . There is no benefit of hemoglobin normalization on all-cause mortality of dialysis @entity1 or on survival of @entity454 @entity1 with @entity712 or @entity741 . Therefore, prevention of @entity8 may be more efficient than its treatment. @entity101 is one of the major side effects of recombinant @entity1 @entity1307 (rHuEPO) therapy. Multiple factors are involved in rHuEPO-induced @entity101 . High blood pressure can usually be controlled readily in the majority of the @entity1 .

Effect of XXXX on cardiovascular diseases.

@entity1 :: ('9606', 'Species') :: ['human', 'patients'] @entity8 :: ('MESH:D007674', 'Disease') :: ['renal anemia'] @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure', 'cardiac failure'] @entity417 :: ('MESH:D000740', 'Disease') :: ['Anemia', 'anemia'] @entity5691 :: ('MESH:D016534', 'Disease') :: ['increased cardiac output'] @entity5988 :: ('MESH:C565277', 'Disease') :: ['left ventricular dilation'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'Hypertension'] @entity1307 :: ('2056', 'Gene') :: ['erythropoietin'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure', 'chronic renal failure'] @entity4346 :: ('MESH:D017379', 'Disease') :: ['left ventricular hypertrophy'] @entity741 :: ('MESH:D017202', 'Disease') :: ['ischemic heart disease'] @entity299 :: ('MESH:D006331', 'Disease') :: ['cardiac complications', 'left ventricular end-diastolic and end-systolic diameters, and cardiac symptoms', 'Cardiac diseases'] @entity67 :: ('MESH:D018754', 'Disease') :: ['ventricular dysfunction'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity454 :: ('MESH:D007676', 'Disease') :: ['end-stage renal disease']
@entity1307 :: (2056,Gene) :: ['erythropoietin']
